Prospective study of safety and usefulness of transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors

Prospective study of safety and usefulness of transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors - Transcatheter arterial chemo- embolization by miriplatin and lipiodol for thoracic malignant tumors

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024322

Enrollment

Registered

2016-10-11

Start date

2016-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic malignant tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Thoracic malignant tumros which can be treated by transcatheter arterial chemo- embolization. 2. The patients who are difficult to be treated by surgery, radiotherapy, and chemotherapy. 3. The patients who are not expected by transcatheter arterial embolization. 4. The patients who meet all of those condisitons. Or the operable patients who are judged to be better treated by transcatheter arterial chemo-embolization for decreasing tumors before surgery

Exclusion criteria

Exclusion criteria: 1. The patients without inclusion criteria. 2. The patients with allergy for blood vessel contrast medium. 3. The patients with renal failure. 4. The patients who are judged to be unsuitable by doctors.

Design outcomes

Primary

Measure	Time frame
Tumor response rate and complications	—

Secondary

Measure	Time frame
Local control period and overall survival	—

Countries

Japan

Contacts

Public ContactHiroaki Nomori

Kameda Medical Center Thoracic surgery

hnomori@qk9.so-net.ne.jp0470-92-2211

Outcome results